Talabostat mesylate In the present study we

In the present study, we have put considerable effort on carefully searching for published studies, setting strict criteria for study inclusion. There are some advantages that should be illustrated. Firstly, we have conducted a comprehensive search to identify more eligible studies thus, makes our analysis more persuasive and substantial. Secondly, we assessed quality of enrolled studies by NOS, excluding low quality studies to raise the overall quality. Thirdly, we performed various subgroup analysis by ethnicity, source of controls and so on, in order to provide the sources of heterogeneity and the tumor and/or race markers. Fourthly, results were adjusted according to the recognized formula, ensuring the accuracy of the results. In addition, the stability of these studies was further confirmed by sensitivity analysis, and publication bias was tested by Egger\'s test and Begg\'s funnel plot. However, several drawbacks in our study should also be noted. Firstly, for XRCC1-rs1799782 polymorphism, relatively heterogeneity existed between some studies, although we conducted this analysis with severe inclusion criteria and explicit extraction for data. Therefore, after stratified analysis by source of control, we observed that the subgroup heterogeneity reduced significantly. It can be assumed that the heterogeneity possibly derived from differenced of ethnicity, source of control, HWE status and cancer type. Secondly, we did not obtain sufficient published studies for several polymorphisms, and some small sample sizes studies may not have enough statistical power to prove authentic associations. Thirdly, all of the studies were published in English, exclusion of studies in other languages may influence effects of polymorphisms tested here. Fourthly, although we want to explore the association between all eligible polymorphisms in XRCC Talabostat mesylate and the risk of all urological cancers, however, eligible studies were only identified for the three most commonly researched cancer types (PCa, BC and RCC). Follow-up studies will continue to focus on this issue. Last but not least, our unadjusted estimated results were lacking in information for data analysis, which might lead to failure to confirm marginal association. Hence, result presented here should be interpreted with care, and future studies with more covariates are required. In conclusion, our meta-analysis suggests that XRCC1-rs25489 polymorphism is a risk factor for urological neoplasms, particularly for BC. Further studies with larger sample size are needed to validate our findings.
Conflicts of Interests
Funding Sources This work was supported by the Clinical Key Subjects Program of the Ministry of Public Health (Urology) and National Natural Science Foundation of China (81370856 and 81401518).
Author Contributions
Acknowledgements
Introduction Traditionally, the evaluation of pathogenicity from enteric infections in the host has focused on the evaluation of defined diarrheal or acute gastrointestinal illnesses and the health outcomes associated with such illness perceived as binary, that is, either death or survival. It has been posited that the host response to frequent enteric infections alters the gut in a way that adversely affects the health status of the host even in the absence of diarrhea or acute gastrointestinal illness. The consequences of this altered host phenotype may have long term effects on child health and development potential. This condition is known as environmental enteropathy (EE). A proposed consequence of EE is reduced linear growth in children (Lunn, 2000; Keusch et al., 2013; Keusch et al., 2014), and EE may explain the less than expected effectiveness of nutritional interventions to improve growth in developing populations (Lunn et al., 1991; Humphrey, 2009; Korpe & Petri, 2012; Kosek et al., 2014). Several mechanisms have been proposed to explain how EE results in poorer nutritional status by reducing functional capacities of the gut. These include reduced absorptive capacity (Kelly et al., 2004; Menzies et al., 1999), increased permeability (Lunn et al., 1991), and chronic intestinal and systemic inflammation with resulting metabolic changes that affect nutrient and micronutrient availability and utilization (Campbell et al., 2003; Kosek et al., 2013).